Mapk
A topic on our watch list — we track its coverage across 3 domains, including Pubmed Targeted, Preprint and Gi Journal.
If Mapk is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- TPD52 promotes breast cancer cell migration, invasion and proliferation via activation of the MAPK/ERK signaling pathway · medRxiv Oncology · 2026-08-10
- Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myeloma · bioRxiv Cancer Biology · 2026-08-07
- Co-targeting deregulated WNT and MAPK signaling pathways limits phenotypic reprogramming of intestinal stem cell progeny in KRAS hyperactivated colorectal cancer. · Cancer Res · 2026-07-28
- KRAS Mutations Predict Inferior Post-Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations. · Eur J Haematol · 2026-07-24
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. · Sci Rep · 2026-08-13
- A pathway-dependency framework for acquired resistance to targeted therapy in EGFR-mutant, KRAS G12C-mutant, and BRAF V600E-mutant NSCLC. · Pharmacol Res · 2026-08-06
What the reporting says
It shows up alongside Colorectal Cancer (12), KRAS (12), Pi3k (9).
Two steps out: AI (through Colorectal Cancer, 12 shared stories on the weaker link); Braf (through Colorectal Cancer, 12 shared stories on the weaker link); Chen (through Colorectal Cancer, 12 shared stories on the weaker link); China (through Colorectal Cancer, 12 shared stories on the weaker link).
Tracked since Mar 15, with coverage on 24 separate days — concentrated in Pubmed Targeted and Oncology.